Insulet Corporation
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 2007年5月15日
- 従業員数
- 5,400
- 公式サイト
- www.insulet.com
総合バリュエーションレンジ · 保守的 $110–$120 / 妥当 $120–$160 / 楽観的 $170–$190。$145.76 時点で 妥当な本源的価値レンジ内。
レポート公開時 $144.94(2026年5月31日)
この銘柄のレポートはお使いの言語でまだありません。
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
沿革
近日公開このセクションは現在準備中です。近日公開予定です。
業界での地位
近日公開このセクションは現在準備中です。近日公開予定です。
